Real-World Evidence: Cyclin-Dependent Kinase 4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast CancerPremiere Date: Monday, April 27, 2020
This activity offers CE credit for:%>
- Physicians (CME)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Tuesday, April 27, 2021
Note: Credit Is No Longer Available
|Martine J. Piccart, MD, PhD
Honorary Professor of Oncology
Universite Libre de Bruxelles (ULB)
Jules Bordet Institute
While clinical trials are designed to demonstrate efficacy and safety under controlled conditions, the highly selected trial populations in these studies often do not accurately reflect the general cancer patient population. The use of real-world data (RWD) to generate real-world evidence (RWE) that reflects the complexity of usual treatment patterns of oncology care and clinical outcomes represents a broader spectrum of patients and can help provide guidance on how to apply randomized, controlled trial (RCT) results more broadly.
The potential for RWE is particularly significant in oncology settings, as the optimal use of agents cannot be fully characterized prior to routine clinical use. RWE, when effectively deployed, can help bridge the gap by aiding in increasing external validity and generating evidence on the factors that determine treatment effects in the real world.
This CME Outfitters Snack will feature expert faculty discussing RCTs, RWD, and RWE, with a focus on the current RWE in the field of cyclin-dependent kinase (CDK) 4/6 inhibitors in metastatic breast cancer (MBC).
At the end of this CE activity, participants should be able to:
- Analyze real-world evidence in terms of study validity, study design, and data source to accurately interpret findings in an oncology setting.
- Assess evidence on real-world, clinical experience for CDK 4/6 inhibitors in MBC.
Supported by an educational grant from Pfizer Inc.
Oncologists, hematologists, oncology nurses, oncology pharmacists, nurse practitioners, pathologists, and surgeons
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Bethesda, Maryland, USA. Please retain your certificate as proof of completion.
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Piccart reports that she receives grants to her institute from AstraZeneca; Eli Lilly and Company; Genentech, Inc./Roche; Merck Sharp & Dohme (MSD); Novartis; Pfizer Inc.; Radius Health, Inc.; Servier; and Synthon. She is on the advisory committee as a Scientific Board Member for Oncolytics Biotech, Inc. She is a consultant for AstraZeneca; Camel-IDS; Crescendo Biologics; Debiopharm; Eli Lilly and Company; F. Hoffman-La Roche Ltd; G1 Therapeutics, Inc.; Genentech, Inc.; Huya Bioscience International; Immunomedics; MSD; Novartis; Odonate Therapeutics, Inc.; PeriphaGen, Inc.; Pfizer Inc.; Seattle Genetics, Inc. and The Menarini Group.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Poshala Tish Aluwihare, PhD (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).